Between biology and benefit: who gains from PARP-immunotherapy in p53-abnormal endometrial cancer?

International Journal of Gynecological Cancer 2026

View at publisher

Authors: Aniceto Lopes da Silva Neto, Juliana Mandarano de Mattos, Júlia Chain Martins, Mariana Scaranti

DOI: 10.1016/j.ijgc.2026.104747

Cited by: 1

References: 5

Fields of Study & Subjects

Endometrial and Cervical Cancer Treatments PARP inhibition in cancer therapy Cervical Cancer and HPV Research

References 5